Forward-looking organizations use real-world data long before a product reaches commercialization. If you’re a clinical operations leader, the pressure to design and execute efficient trials has never been higher. Timelines...
In the fast-paced world of drug development, every investment decision is a balancing act. For Biotech startups, Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) solutions can feel...
BioBridges is pleased to announce the appointment of Larry Blandford, PharmD, to its Board of Directors. He will play a key role in shaping BioBridges’ strategic vision and expanding the...
The future of HEOR was highlighted at the ISPOR 2025 conference as global thought leaders gathered to discuss emerging trends, innovations, and challenges. From groundbreaking applications of generative AI to...
By Manvi Sharma, PhD, Director of Real-World Evidence The life sciences industry is evolving rapidly, and the ability to harness real-world evidence (RWE) in life sciences is becoming a key...
The life sciences job market is experiencing significant shifts, and we anticipate this will continue throughout 2025 with a greater focus on roles that support product innovation, regulatory compliance, emerging...
The HEOR industry is constantly evolving – from new EU HTA regulations to the impact of AI. Our team recently attended ISPOR Europe in Barcelona, Spain, where John Cook, our Chief Scientific Officer, gave us his take on the compelling topics people were discussing this year.
BioBridges now offers complete Health Economics and Outcomes Research (HEOR) services. HEOR is a field of research that provides real-world data and insights to demonstrate the clinical and economic value of pharmaceutical products and medical devices.
CHEORS Acquired by PharmAlliance PharmAlliance Announces the Acquisition of CHEORS Per the BusinessWire BioBridges is excited to be part of PharmAlliance, a growing pharmaceutical and life sciences services platform....
